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Abstract
Purpose The majority of targeted personalized cancer
therapies are effective only in part of the patients, and most
of these drugs are excessively expensive. Therefore,
methods are urgently required, which reveal already early
during treatment, whether the therapy is effective. In the
present report, monitoring of circulating epithelial tumor
cells (CETC) was used as a timely control of trastuzumab
therapy in patients with HER2/neu-positive breast cancer.
Methods Seventy-nine sequential HER2/neu-positive
breast cancer patients, 35 without trastuzumab, and 36
treated with 1 year of trastuzumab treatment were inclu-
ded. CETC from unseparated white blood cells stained with
FITC-anti-EpCAM were analyzed repeatedly during che-
motherapy and between 2 and 10 times during 1 year of
maintenance treatment or observation.
Results Patients treated with trastuzumab had a better
relapse-free survival than patients without trastuzumab
treatment during the first 2–4 years of follow-up. Decrease
in numbers or no change versus highly variable numbers or
increase (fivefold or more) allowed to discriminate highly
significantly and clearly (P \ 0.0001, hazard ratio 5.5)
between patients with a low or high risk of relapse. An
increase in CETC was accompanied by an increasing
portion of cells containing a very high number of HER2/
neu gene amplificates.
Conclusions Analysis of the behavior of CETC can, in
the future, contribute to evaluate the efficacy of targeted
therapy early during the course of the disease, sparing
patients unnecessary treatment but also to reduce the costs
for the health system and to downsize the extent and length
of clinical studies.
Keywords HER2/neu-positive breast cancer  Circulating
epithelial tumor cells  Trastuzumab therapy  Cancer
therapy
Purpose
The majority of targeted personalized cancer therapies
have, so far, failed to demonstrate convincing efficacy, and
even the few active agents, the most successful of which is
trastuzumab, are effective only in part of the patients car-
rying the respective targets. In 20–25% of invasive breast
cancers, the ErbB2 growth factor receptor is overexpressed
mainly due to an amplification of the HER2/neu gene and
patients with this amplification have an inferior prognosis.
The insight into the molecular mechanisms of this genetic
aberration allowed the development of a number of mole-
cules directed to the ErbB2 receptor such as the humanized
antibody trastuzumab, a monoclonal antibody aimed at the
extracellular juxtamembrane domain of HER2/neu
(O’Donovan and Crown 2007), which enabled one of the
first targeted therapies in combination with standard adju-
vant therapy, thus decreasing the risk of recurrence (Hudis
2007; Olopade et al. 2008).
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Although our understanding of the molecular events that
underlie tumor development including gene expression
profiling has improved treatment, only part of those
patients, carrying the HER/2neu overexpression, respond to
the targeted therapy and a considerable number of patients
would farewell also without trastuzumab (77% at 2 years
observation; Piccart-Gebhart et al. 2005), To date, statis-
tical methods taking several years before results are
available are still the only manner of determining the
efficacy of the applied treatment, and later investigations
often do not confirm initial results. Thus, Spielmann et al.
(2009) presented a 3-year follow-up of the phase III PACS-
04 trial where the difference in disease-free survival
between the observation arm and the trastuzumab arm in
contrast to the previously published difference of 8.4%
from the Hera study (Piccart-Gebhart et al. 2005) nearly
disappeared (73.2% vs. 72.7%). This shows that even with
time-consuming studies it is difficult to assure the benefit
of a new therapy in medical trials. Most of these drugs are
excessively expensive straining the health systems of the
developed countries and being prohibitive in the develop-
ing world. In addition, a high proportion of patients may
farewell also without trastuzumab and prediction for the
individual patient is restricted. Therefore, methods are
urgently required, which can determine early on whether
and how patients respond to the applied therapy and which
can evaluate the individual patient’s response to treatment
earlier and continuously.
One approach to gauge the specific response to therapy
in the individual patient is monitoring the size reduction in
the tumor during primary (neoadjuvant) therapy. In previ-
ous reports, the importance of circulating tumor cell
monitoring (Pachmann et al. 2001, 2005a) in peripheral
blood for determination of chemotherapy efficacy in con-
junction with neoadjuvant therapy had already been dem-
onstrated. We have shown that circulating tumor cells in
the neoadjuvant setting respond to therapy in a way iden-
tical to the tumor (Pachmann et al. 2005b). However, a
good response to neoadjuvant treatment does not neces-
sarily translate into better prognosis in biologically more
aggressive breast cancers (Darb-Esfahani et al. 2009).
Indeed, after the initial reduction during neoadjuvant che-
motherapy, we reported a subsequent massive dissemina-
tion of cells from the shrinking tumor (Camara et al. 2007),
which are spread via peripheral blood and, if not treated
adequately, can grow into metastases (Staal et al. 2009).
We were able to show that the response of CETC to
chemotherapy is also applicable for monitoring therapy
response in the adjuvant situation and that this is highly
correlated to relapse-free survival (Pachmann et al. 2008).
We had prospectively analyzed patients with HER2/neu-
positive breast cancer for their behavior of circulating
tumor cells without trastuzumab before trastuzumab was
included into the guidelines of treatment for HER2/neu
breast cancer, and these patients were used as the control
population, whereas at present a control population of
patients with this disease deprived of trastuzumab will no
longer be available because of ethical reasons.
In the present work, the impact of trastuzumab on CETC
in peripheral blood after adjuvant chemotherapy was lon-
gitudinally monitored, quantifying the number of these
cells during or without adjuvant trastuzumab therapy in
individual HER2/neu-positive patients and their HER2/neu
amplification status in order to investigate whether it is thus
possible to assess the efficacy of this treatment and its
correlation to clinical outcome.
Methods
Patients and treatment
Seventy-nine sequential patients were included in the study.
All patients consented with written informed consent to
blood drawing at the onset of treatment according to ethics
committee approval. (Approved by the local ethics com-
mittee. Ethik Kommission der Friedrich Schiller Universita¨t
Jena an der Medinischen Fakulta¨t, Jena, Germany). Clinical
data were collected from the unit’s database and updated
periodically. HER2/neu status was routinely determined
immunohistochemically, and in cases of doubt, additionally
verified by FISH. 35 patients diagnosed as positive (IHC
3?) had not received adjuvant trastuzumab between Sep-
tember 2001 and September 2005 representing the control
group. 36 patients overexpressing HER2/neu received
adjuvant chemotherapy followed by 1 year trastuzumab
between 2005 and February 2008. 8 patients were primarily
metastasized and received chemotherapy together with
trastuzumab. Adjuvant chemotherapies applied were epir-
ubicin/cyclophosphamide (EC) with or without taxane,
fluorouracil/epirubicin/cyclophosphamide (FEC) with and
without taxane, fluorouracil/epirubicin/cyclophosphamide
(FEC)/taxane/gemcitabine, and cyclophosphamide/metho-
trexate/fluorouracil (CMF). All estrogen receptor (ER)
positive patients were administered hormone therapy after
adjuvant chemotherapy.
CETC analysis
About 2–7 ml of blood anticoagulated with EDTA was
drawn at each visit before and during chemotherapy and
during 1 year of trastuzumab maintenance therapy or fol-
low-up at least twice and up to 10 times. In order to adjust
for shipping delays, all samples were analyzed 48 h after
blood drawing including exclusively viable cells into the
analysis. 1 ml of blood was lysed with ammonium chloride
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(Qiagen, Hilden, Germany). For detection of CETC, white
cells from the sediment were subject to MAINTRAC
analysis, omitting all enrichment steps, diluting the pellet
in 500 lL of phosphate-buffered saline (pH 7.4) and adding
12.5 lL of fluorescein isothiocyanate-conjugated mouse
antihuman epithelial antibody (EpCam) (Miltenyi Biotec,
Bergisch Gladbach, Germany) and, optionally, 5 lL of
phycoerythrin-labeled CD45 (Miltenyi Biotec) simulta-
neously for 15 min in the dark. Propidium iodide (PI) or
7AAD was added for recording dead cells. Analysis of red
and green fluorescence of the cells was performed using a
laser scanning cytometer (LSC Compucyte Corporation,
Cambridge, MA), enabling relocation of cells for visual
examination of vital epithelial cells (which were always
CD45 negative) as extensively described in a previous
study (Pachmann et al. 2005a) or image analysis using a
ScanR microscope (Olympus, Hamburg, Germany). For
LSC measurements, a defined volume of the cell sus-
pension was applied to a defined area on an adhesion slide
(Menzel Gla¨ser, Braunschweig, Germany) and measure-
ments were performed on this area. Cells were detected by
their forward scatter and red and green fluorescence
recorded (Pachmann et al. 2005a). CD45 staining contrib-
uted to better separate brightly staining lymphocytes and
faintly staining granulocytes from the CD45-negative epi-
thelial cells that were selected and gated by their green
fluorescence and relocated and analyzed for vitality by
propidium iodide exclusion. Morphological analysis had
already been performed previously, and a fluoromicrograph
of a typical group of four epithelial antigen-positive cells
(taken from Pachmann et al. 2001) is shown in Fig. 1a.
Three of the cells display tiny caps, whereas the fourth
exhibits strong staining, which was considered as intra-
cellular staining. Indeed, hematoxylin–eosin staining (HE)
in Fig. 1b reveals that this cell is a dying cell. In addition, a
normal epithelial antigen-negative leukocyte is visible only
in HE staining. In all further analyses, vitality was analyzed
by PI or 7AAD exclusion. Only vital cells were counted.
For ScanR image analysis, defined volumes of cell sus-
pension were added to glass bottom microtiter plate wells
and analysis began when the cells had settled on the well
bottom. Figure 1c shows a fluoromicrograph including two
vital epithelial antigen-positive cells with typical green
caps, adjacent to two faintly CD45-stained granulocytes
and a bright CD45-stained vital lymphocyte in addition to a
dead PI-positive cell. In Fig. 1d, an overlay of a fluoro-
micrograph with transmitted light is shown. Note, the red
7AAD-positive fluorescing nucleus of a dead normal leu-
kocyte in the neighborhood of the green fluorescing CETC
and a red and green fluorescing dying CETC. Results from
both microscope analyses were highly comparable.
Sequential analyses for individual patients were always
performed on the same instrument. Numbers of live CETC
were calculated per ml. As seen from Fig. 3, CETC num-
bers were already strongly influenced by chemotherapy and
varied before the start of trastuzumab therapy between 100
and a maximum of 30,000. These values are much higher
than those reported earlier (Lobodasch et al. 2007) in pri-
mary breast cancer and as detected by the CellSearch
approach (Cristofanilli et al. 2004) in metastatic breast
cancer due to omission of magnetic separation because
magnetic separation may lead to an extensive loss of spe-
cific cells (Pachmann et al. 2005a) as supported by a
recently published report (Coumans et al. 2010). Previous
studies with our approach had revealed 97% specificity and
92% sensitivity (Pachmann et al. 2005a), and analysis of 25
patients with hematological malignancies did not show any
EpCam-positive cells in any of the patients whether with
full blown leukemia, in complete remission with regener-
ating hematopoiesis, or in relapse (Pachmann et al. 2005b).
In the longitudinal analysis during therapy, a continuous
reduction or increase of fivefold or more over the obser-
vation time of 1 year was defined as a significant decrease
or increase. In situ hybridization was subsequently per-
formed in selected patients.
FISH (fluorescence in situ hybridization) analysis
About 100 ll of unstained cell suspension were prepared as
described above. 3 ll of FITC-HEA were added followed
by cold incubation for 15 min. No PE-CD45 (orange) was
used in order to avoid interference with the fluorescent
HER2-DNA probe (red).
The cell suspension was then diluted with 10–900 ll of
PE buffer depending on the assessed CETC density. An
equal volume of BSA 4% was added. The marked area on
the slide comprised about 1 cm2. The slides were then air-
dried for at least 8 h in a dark place. Storage up to
3 months before further processing was possible without
loss of quality if kept in the dark. The FISH analysis was
performed using Path Vision HER2 DNA probe kit (LSI
HER-2/CEP17 probe, Abbott GmbH and Company, KG,
Wiesbaden-Delkenheim, Germany). The manufacturer’s
protocol was adapted to a fixed cell suspension instead of
paraffin-embedded tissue. Fixation of the cells was
achieved by incubating the slide in paraformaldehyde for
10 min followed by treatment with Protease K. After
incubation in post-hybridization washing buffer (2X SSC
and 0,3% NP-40) for 5 min, denaturation was performed in
heated formalin at 72C for 5 min followed by dehydration
in ethanol at 70, 85, and 96% for 1 min each. 1.5 ll of the
denaturated DNA probe, including a HER2 DNA probe
labeled with SpectrumOrange and a CEP17 alpha DNA
probe labeled with SpectrumGreen, was used for hybrid-
ization with incubation for 14–18 h at 37C in a humidified
chamber. Then, slides were washed with post-hybridization
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Fig. 1 a Fluoromicrograph of a typical group of four epithelial
antigen-positive cells (taken from Darb-Esfahani et al. 2009). Three
of the cells display tiny caps, whereas the fourth exhibits strong
staining, which was considered as intracellular staining. b Hematox-
ylin–eosin staining (HE) reveals that the intracellularly stained cell is
a dying cell. In addition, a normal epithelial antigen-negative
leukocyte is visible only in HE staining. c Fluoromicrograph of
epithelial cells with green fluorescence, exclusively surface located
including two vital epithelial antigen-positive cells with typical green
caps (green arrows), adjacent to two faintly CD45-stained granulo-
cytes (white arrows) and a bright CD45 stained vital lymphocyte (red
arrow) in addition to a dead PI-positive cell (orange arrow).
d Overlay of a fluoromicrograph with transmitted light. Note, the
red 7AAD-positive fluorescing nucleus of a dead normal leukocyte in
the neighborhood of the green fluorescing CETC and a red and green
fluorescing dying CETC. e Two CETC from the same patient using
the green and red filter, respectively. In both cells, the typical green
cap of the EpCam, and in addition, the two green signals of the
CEP17 alpha DNA probe can be identified. The upper cell carries
only two HER2/neu signals, whereas in the lower cell more than 10
signals can be detected. f Fluoromicrograph overlay of the HER2/neu
FISH analysis of a group of tumor cells from a breast cancer patient:
besides the normal blood cells (nuclear stain was DAPI, only the
nuclei are visible), one can see a group of tumor cells staining with
typical green caps with the FITC-labeled anti-EpCAM. These cells
carry a varying quantity of HER2/neu amplifications (pink-red dots in
the cell nucleus)
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washing buffer at room temperature for 1 min and subse-
quently at 72C for 2 min. After drying, 4,6-diamidino-2-
phenylindol (DAPI) was applied for counterstaining of the
nuclei. An Axiovert fluorescent microscope (Zeiss Jena
Germany) with suitable filters was used for cell analysis
with a 1009 oil immersion objective. Epithelial cells were
identifiable by a typical green staining of the surface as
mentioned above; DAPI staining confirmed integrity of the
nucleus. Now, all the red signals within the nucleus were
counted, which led to a classification of each cell as fol-
lowing: cells containing 2–5, 6–10, or [10 signals. The
number of centromeres labeled by the CEP17 DNA probe
was assessed. 20 consecutive CETC per sample were
analyzed and the percentage of each class of signals was
calculated.
According to the most recent recommendations by the
ASCO (American Society of Clinical Oncology), cells
with more than 6 signals were considered amplified.
However, most previous researchers referred to [4 signals
as HER2 amplification. In Fig. 1e, two CETC from the
same patient are shown with the typical green cap of the
EpCam and the two green signals of CEP17. The upper
cell carries only two HER2/neu signals, whereas in the
lower cell more than 10 signals can be detected. A flu-
oromicrograph of a group of cells comprising leukocytes
and CETC is shown in Fig. 1f. The high variability in
HER2/neu amplification in this cell group from one
patient is obvious.
Statistics
For survival analyses, we used Kaplan–Maier plots and an
analysis over strata and a Cox regression analysis of the
SPSS statistical program (SPSS Inc, Chicago, IL). The
discriminatory power of the analysis of the behavior of the
circulating cells over time (decrease or increase) was high
enough that a calculation assuming a power of 80%
showed that the patient population necessary was reached
(Sobrero and Bruzzi 2009).
Results
Table 1 gives an overview of the 79 consecutive patients
treated with and without trastuzumab therapy at our insti-
tution. 20 patients have suffered relapse during the obser-
vation period: 15 in the group without adjuvant
trastuzumab in part due to the longer observation time and
5 in the group receiving trastuzumab. Among the 8 patients
with primary metastasized tumors, 5 progressed during the
observation period. The baseline characteristics of the
untreated and the trastuzumab-treated groups were well
balanced with respect to tumor size, estrogen receptor
expression, HER2/neu expression, and lymph node status
with a somewhat higher frequency of anthracycline-based
therapies in the trastuzumab-treated patients.
Kaplan–Meier relapse-free survival curves from the 35
patients without trastuzumab and the 36 patients treated for
1 year with trastuzumab are shown in Fig. 2. Although this
was not a randomized study, outcome characteristics at
2 years were well comparable to the larger studies (Joen-
suu et al. 2006; Piccart-Gebhart 2006; Romond et al. 2005)
and the difference in chemotherapeutic regimen could at
most have contributed to the better outcome of the trast-
uzumab treatment group. However, our patients were
observed another 4–6 years in a prospective follow-up
beyond the time of 2 years, results which are still lacking
from the NCT 00045032 trial. There was a trend to longer
relapse-free survival in our restricted patient sample of
HER2/neu-positive patients treated with 1 year sequential
trastuzumab after chemotherapy compared to a patient
sample not receiving trastuzumab therapy; however, this
did not reach statistical significance (Fig. 2). The Kaplan–
Meier plots indicate that the highest benefit occurred
between years 2 and 3 after diagnosis. Thereafter, the
curves tended to merge. But, even in the group not treated
with trastuzumab, 50% of patients were still alive without
relapse after 5 years. There was, however, no plateau and
relapses occurred continuously. Patients with primarily
metastasized tumors, although receiving trastuzumab
simultaneously with chemotherapy, had the poorest
prognosis.
Since lymph node involvement is a confirmed negative
prognostic factor, we examined the influence of lymph
node status in trastuzumab-treated and untreated patients.
In the control group with no trastuzumab therapy, there was
no significant difference between lymph node-negative
patients and lymph node-positive patients, whereas under
trastuzumab therapy HER2/neu-positive patients without
lymph node involvement had a tendency to better prog-
nosis than patients with positive lymph nodes (P = 0.113)
(not shown).
The question arises; what is the effect of the antibody
which is directed to the remnant systemic part of the tumor,
the circulating tumor cells, and why is the benefit of
trastuzumab limited and obviously only lasts for a restric-
ted time?
In our institution, prior to the establishment of trast-
uzumab therapy, HER2/neu-positive patients were already
being monitored prospectively for their numbers of CETC
during chemotherapy treatment and the further course of
disease. These patients now provided a unique source for
further analyzing the factors contributing to relapse-free
survival.
In almost all patients, CETC were detected before
therapy and even after systemic chemotherapy still varying
J Cancer Res Clin Oncol (2011) 137:1317–1327 1321
123
numbers of circulating tumor cells were detectable. Anal-
ysis of circulating tumor cells in blood is comparable to a
snapshot; therefore, rather than individual values, the ten-
dency of the alterations was parsed and the behavior
classified as either decreasing/stable or highly variable and/
or increasing during the year of treatment with trastuzumab
or, if relapse occurred earlier, until relapse. In patients
without trastuzumab, the behavior of CETC during the
same time was recorded. Figure 3 shows examples of
representative courses of CETC. In Fig. 3a, typical courses
during maintenance therapy with trastuzumab with
decreasing CETC are shown and all of these patients are
still in complete remission. Typical courses of CETC in
patients with highly variable or increasing CETC are
shown in Fig. 3b. Two of these patients have suffered
relapse. CETC behavior without trastuzumab was compa-
rable, but it should be mentioned that the highly variable
saw-toothed characteristics were mainly seen in the trast-
uzumab treatment group. Figure 3c, d show typical CETC
courses in patients without trastuzumab treatment. All three
of the patients with increasing CETC have already
relapsed. In Fig. 3e, f, two patients are shown where
decrease as well as increase in CETC during trastuzumab
was accompanied by an increase or decrease in the fraction
of cells with high amplificates of the HER2/neu gene,
suggesting that response or resistance to therapy may be
mainly due to this population of cells. This phenomenon is
now being further investigated.
For some patients in the observation group, only single
measurements were available, therefore increase/decrease
in cell numbers could not be determined. Still, the difference
in outcome between patients with decreasing and increasing/
variable numbers of CETC was highly significant both
Table 1 Overview of the
clinical data of patients
analyzed for CETC without and
with trastuzumab treatment
HR hormone receptor, CR










79 (100%) 35 (44%) 36 (46%) 8 (10%)
HR positive 55 (70%) 23 (66%) 26 (72%) 0.434 6 (75%)
HR negative 23 (29%) 12 (34%) 9 (25%) 2 (25%)
NA 1 (1%) 0 (0%) 1 (3%) 0 (0%)
Age 58 60 55 60
HER2/neu-positive 74 (94%) 33 (94%) 35 (97%) 0.307 6 (75%)
HER2/neu negative 3 (4%) 1 (3%) 0 (0%) 2 (25%)
NA 2 (2%) 1 (3%) 1 (3%) 0 (0%)
Tumor status T1 48 (61%) 22 (63%) 22 (61%) 4 (50%)
Tumor status T [ 1 28 (35%) 11 (31%) 13 (36%) 4 (50%)
NA 3 (4%) 2 (6%) 1 (3%)
Lymph node status N0 42 (53%) 19 (54%) 20 (55%) 0.916 3 (37%)
Lymph node status N1 35 (45%) 15 (43%) 15 (42%) 5 (63%)
NA 2 (2%) 1 (3%) 1 (3%) 0 (0%)
CR 54 (68%) 20 (57%) 31 (86%) 3 (37%)
Relapse 25 (32%) 15 (43%) 5 (14%) 0.007 5 (63%)
CETC
Decrease 46 (58%) 19 (54%) 25 (69%) 2 (25%)
Increase 26 (33%) 9 (26%) 11 (31%) 6 (75%)
NA 7 (9%) 7 (20%) 0 (0%) 0 (0%)
Fig. 2 Results from 36 HER2/neu-positive patients treated with
1 year sequential trastuzumab after chemotherapy (green line) as
compared to a historical patient sample of 35 patients not receiving
trastuzumab therapy (red line)
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during maintenance therapy with trastuzumab or observa-
tion (Table 2).
Including the behavior of CETC into the Kaplan–Meier
analysis allowed for a clear separation of patients with
highly variable or increasing CETC with inferior prognosis
from those with decreasing or no change in CETC with a
good prognosis in all treatment groups. In Fig. 4, the
behavior of CETC in the control group (dashed lines) and
in the trastuzumab group (thin lines) is compared for
relapse-free survival. In both groups, patients with a
decrease in CETC had a highly significantly better cumu-
lative survival (green lines) than patients with increasing
CETC (red lines). Even without trastuzumab treatment, a
decrease in CETC was associated with excellent survival,
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Fig. 3 Typical courses of CETC numbers from 3 individual patients
each. Values on the negative x-axis are cell values during chemo-
therapy, while on the positive x-axis, the values during trastuzumab
therapy are plotted. a Typical courses for three individual patients
during chemotherapy followed by 1 year of trastuzumab decrease
under trastuzumab with decreasing CETC. b Typical courses of
CETC in patients during chemotherapy followed by 1 year of
trastuzumab with highly variable or increasing CETC during
maintenance therapy with trastuzumab CETC. c, d Typical CETC
courses in patients without trastuzumab treatment. All three of the
patients with increasing CETC have already relapsed. e, f Two
patients with decrease as well as increase in CETC during
trastuzumab and increase or decrease in the fraction of cells with
different amplificates of the HER2/neu gene. The fraction of cells
with different amplificates of the HER2/neu gene is given on the left
y-axis
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whereas most patients with highly variable or an increase
in CETC would eventually suffer a relapse. The same was
true for the group receiving trastuzumab, where all
relapsing patients except one were in the group with an
increase in CETC, and this was obvious in spite of the
relatively short observation time. This was also true for
progress in the primarily metastasized patients (dotted
lines). This difference in the behavior of CETC (increase or
decrease) was independent of lymph node involvement
both in patients without and with trastuzumab treatment.
The survival curves for patients with increasing and
Table 2 Outcome of patients with decreasing and increasing/highly
variable numbers of CETC during maintenance therapy with trast-
uzumab or observation
Total Relapse Complete remission P
No trastuzumab
Decrease 19 4 15 0.004
Increase 9 7 2
Trastuzumab
Decrease 25 1 24 \0.001
Increase 11 7 4
Fig. 4 a Kaplan–Meier relapse-free survival curves for patients
without trastuzumab (green line decreasing/stable CETC, red line
increasing/variable CETC). b Kaplan–Meier relapse-free survival
curves for patients with trastuzumab (green line decreasing/stable
CETC, red line increasing/variable CETC). c Combined Kaplan–
Meier relapse-free survival curves for patients with increasing and
decreasing CETC in the untreated, the trastuzumab-treated and the
primarily metastasized patients receiving trastuzumab together with
chemotherapy (dashed lines patients without trastuzumab treatment;
red line patients with increasing or variable CETC numbers; green
line patients with decreasing or stable CETC numbers). Solid lines
patients with trastuzumab treatment; red line patients with increasing
or variable CETC numbers; green line patients with decreasing or
stable CETC numbers. Dotted lines primarily metastasized patients;
red line patients with increasing or variable CETC numbers; green
line patients with decreasing or stable CETC numbers. Fat lines all
patients combined independent of treatment; red line patients with
increasing or variable CETC numbers; green line patients with
decreasing or stable CETC numbers
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decreasing CETC in the untreated, the trastuzumab treated,
and the primarily metastasized patients are combined in the
fat lines demonstrating a highly significant separation
between poor and good prognosis patients in all three
groups according to the behavior of CETC, independent of
disease stage and treatment. In a cox regression analysis,
joint analysis of CETC, nodal status, tumor size, and ER
status resulted in a regression model in which only CETC
behavior significantly influenced the relapse-free survival.
Thus, the response of CETC to therapy makes it possible
to distinguish not only between groups, but also individual
patients with different outcomes already during therapy.
Discussion
Based on the results of three studies, trastuzumab therapy is
now included into the 2008 ASCO/CAP guidelines as
routine therapy and nearly all HER2/neu-positive patients
are treated with trastuzumab today (Joensuu et al. 2006;
Piccart-Gebhart 2006; Romond et al. 2005; Slamon et al.
2006). Therefore, it was only possible to compare a his-
torical group of control patients not treated with trast-
uzumab with the trastuzumab-treated patients; a trend to
better relapse-free survival in patients treated with trast-
uzumab was also observed in the patients from our insti-
tution, which after four and a half years was, however, no
longer statistically significant. This might be due to the
relatively low number of patients, but it is obvious that for
the trastuzumab-treated patients, the relapse-free survival
curve is shifted to the right during the first 3 years and then
declines. This indicates that the benefit from 1 year of
trastuzumab treatment seems to last mainly for the first
3 years. Since also some of the patients with HER2/neu-
positive breast cancers before the era of trastuzumab
seemed to fare well, it would be desirable to analyze more
closely which patients benefit from trastuzumab. This may
no longer be possible when in the future all HER2/neu-
positive patients will receive trastuzumab therapy and even
node-negative HER2/neu-positive grade 1 or 2 cancers
(Tovey et al. 2009) are no longer classified as ‘‘low risk’’.
In our HER2/neu-positive patients in context with
trastuzumab treatment, the difference between lymph node-
negative and -positive patients was not significant. Both
lymph node-negative and -positive patients benefited from
trastuzumab. The shift to later relapse in patients receiving
trastuzumab indicated that relapse was postponed but not
averted.
In the primarily metastasized patients, 5/8 patients pro-
gressed in spite of simultaneous chemotherapeutic and
trastuzumab treatment. The poor outcome of this group
might illustrate the limited efficiency of chemotherapy in
the presence of trastuzumab. If it is assumed that
trastuzumab drives the cells into a resting stage, this would
impair the effect of chemotherapy, which is directed
preferentially to growing cells, and this might be the cause
of a negative interaction with cell cycle-dependent che-
motherapy (Lenferink et al. 2001). Such interactions might
be the reason for ‘‘combinations’’ of biologically based
targeted and traditional chemotherapeutic leading to both
successes and failures (Peng et al. 1996; Ling et al. 2007;
Vogel and Tan-Chiu 2005). This is also in line with our
previous results that have shown that during neoadjuvant
treatment sequential trastuzumab therapy leads to better
outcome than simultaneous treatment (Gajda et al. 2008).
The unexpectedly long survival of one primarily metasta-
sized patient during long-time trastuzumab therapy without
further disease progression is in line with the results of
Livingstone and Johnstone, showing long-term responses
of a fraction of metastasized HER2/neu-positive patients to
trastuzumab (Livingston et al. 2008; Johnston et al. 2009).
The routine use of biomarkers is not recommended for
early breast cancer (Harris et al. 2007) although it would,
undoubtedly, be most beneficial for this group of patients to
have a tool to control response to therapy and, ultimately,
to prevent the spread of disease by adjusting the treatment.
We have previously shown that monitoring CETC during
adjuvant chemotherapy can contribute to this goal and may
in the future help to improve therapeutic results (Pachmann
et al. 2008; Camara et al. 2009).
Having prospectively monitored patients for CETC
during the following observation period or during mainte-
nance treatment with trastuzumab since 2001, we were able
to evaluate the HER2/neu-positive patients for their pattern
of CETC behavior and clinical outcome.
In both the observation and the treatment group, we
could clearly distinguish between patients whose CETC
numbers decreased or remained at constant levels and those
whose CETC numbers increased. Grouping together
patients with a high variability in CETC numbers and
patients with increasing CETC during trastuzumab treat-
ment led to an increase in significance. There was a highly
significant difference in relapse-free survival between these
two populations in the observation only group as well as in
the trastuzumab treatment group. Patients receiving trast-
uzumab, who had decreasing or stable CETC, had an
excellent relapse-free survival, and only one relapse has
occurred during a follow-up time of almost 6 years. This
was true also for patients without trastuzumab therapy with
decreasing CETC during the 8 years of observation.
The population correlating best with the behavior of
total CETC was the group with a high amplification of
HER2/neu, indicating that alternating CETC numbers may
be due to repeated elimination of CETC by trastuzumab
and either re-growth or reseeding possibly from micro-
metastatic loci. In such cases, it might, in the future, be
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meaningful to increase the trastuzumab dose or add lapat-
inib. The effect on the CETC might then be able to tell us
whether this approach is successful. The behavior of the
CETC indicates that there is a biological diversity even in
HER/2neu-positive disease that warrants further studies.
Indeed, monitoring of the response of CETC to trast-
uzumab will provide new insights into the nature and
behavior of these cells (Brockhoff et al. (2007). CETC
monitoring may also help identify biological changes of
HER2/neu status in the process of tumor progression
(Fehm et al. 2007).
On the other hand, not only patients with decreasing
CETC but also with stable CETC had an improved
prognosis. This is compatible with results from Brockhoff
et al. 2007 who observed a reduced fraction of prolifer-
ating cells and prolongation of the G1 phase in vitro and
an increase in quiescent cells but no appreciable amount
of apoptosis during treatment of cell line cells with
trastuzumab. Anti-EGFR agents such as cetuximab, erl-
otinib, as well as trastuzumab have been shown to induce
G1-0 arrest in treated cancer cells (Staal et al. 2009).
Driving tumor cells into quiescence may prohibit them
from forming metastases without eliminating these cells.
Such cells can, however, possibly be reactivated even and
this may be the reason why relapses can occur even after
years.
We here show that monitoring CETC can help identify
patients at high risk for progression already during treat-
ment early on during the course of the disease and,
moreover, that monitoring of the response of CETC to
trastuzumab will provide new insights into the nature and
behavior of these cells.
CETC monitoring might enable patients to be distin-
guished who farewell without trastuzumab treatment,
which may be especially valuable for patients with car-
diovascular risk factors. In such cases, it might be con-
sidered to reserve trastuzumab therapy as long as the tumor
cells remain constant. On the other hand, an increase in or
highly unstable CETC even during trastuzumab treatment
did signal a significantly impaired outcome. Therefore, it
will become possible already during trastuzumab treatment
to get hints about therapy success or failure and this may
help to change and improve therapy.
Conclusion
Thus, although the debate with respect to the ‘‘true’’ number
of tumor cells in the circulation is still not resolved, we were
able to show that the response of the circulating cells was
highly significantly correlated to outcome with a high
hazard ratio (Sobrero and Bruzzi 2009) permitting the
number of patients included in a study to be kept low and
this may, in the future, also help to reduce the size of studies
necessary to determine treatment success.
The behavior of CETC detected in our approach reliably
mirrors the response of the remnant tumor burden to
trastuzumab maintenance therapy and may, therefore, be
applicable as a biomarker for monitoring the efficacy of
targeted therapy in the individual patient.
‘‘Liquid biopsies’’ of the remnant tumor burden may
initiate a paradigm shift because analysis of the systemic
part of the tumor allows determining already during ther-
apy whether the respective treatment is effective in the
individual patient and in which patients treatment should
be changed or complemented. This will reduce lengthy
randomized studies that are able to tell only with a statis-
tical probability and after years whether a compound is
active and thus help to save costs for the pharmaceutical
industry and the health system.
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